A mock recall tests whether a pharmaceutical company can identify affected batches, locate distributed stock, contact relevant parties and reconcile quantities within its approved recall procedure. The exercise should expose weaknesses before a real product defect requires urgent action.

Set an exercise objective and scenario
Choose a plausible scenario such as incorrect strength on a carton, an out-of-specification stability result or a confirmed supplier defect. Specify the hypothetical batch scope and distribution dates. Define whether the exercise is announced or unannounced, and how it will avoid alarming customers or triggering a real market action.
Trace the distribution chain
Start from manufacturing and batch release records, then follow shipments through warehouses, wholesalers, contract logistics providers and relevant export destinations. Check whether customers can be identified at the required level and whether current contact details and responsible persons are available.
Quantity reconciliation
Compare manufactured quantity, released quantity, stock on hand, samples retained, units destroyed, units shipped and quantities accounted for in the simulated recall. A reconciliation gap must be explained; percentages alone can obscure missing high-risk stock. The accounting model must avoid double-counting stock transferred between facilities.
Test communications and escalation
Assess the time needed to notify the recall team, quality leadership, regulatory contacts and distribution partners. For a mock exercise, use clearly marked simulated messages and controlled test contacts. A real recall requires applicable authority notification and the relevant market-specific procedures.
Measure effectiveness
Useful indicators include time to identify all consignees, percentage of shipment records reconciled, completeness of contact details, accuracy of stock status and ability to identify downstream distribution. Targets should be approved before the exercise and reflect risk and procedural expectations.
Illustrative reconciliation
A batch has 10,000 released packs: 1,000 remain in the manufacturer’s warehouse, 8,500 were shipped and 500 were used for approved samples or documented destruction. The shipped quantity is traced to three distributors, but one cannot identify downstream stock. Even though the arithmetic reconciles, traceability effectiveness is inadequate and requires corrective action.
Closeout and CAPA
Issue an exercise report describing scenario, assumptions, participants, chronology, quantity reconciliation, missed contacts, data gaps and corrective actions. Assign owners and dates, and verify effectiveness by targeted retesting or the next exercise. Management review should consider systemic weaknesses.
UK and EU context
For UK and EU operations, confirm the applicable recall responsibilities, competent-authority reporting arrangements, distribution traceability and quality agreement provisions. Refer to EU GMP Chapter 8 and local regulatory guidance rather than assuming one global notification timeline.
Related articles and official guidance
Use this article for education and planning. Current pharmacopoeial requirements, approved methods, product specifications and site procedures govern GMP decisions.


